SELLAS Life Sciences (SLS) Receivables (2012 - 2022)

SELLAS Life Sciences (SLS) reported Receivables of $1.0 million for Q1 2022, down 44.99% quarter-over-quarter from $1.8 million in Q2 2015.

SELLAS Life Sciences (SLS) Receivables (2012 - 2022) Analysis & Trends

SELLAS Life Sciences (SLS) has 5 years of Receivables data on file, last reported at $1.0 million in Q1 2022.

Receivables for Q1 2022 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $1.0 million (changed N/A YoY), and the FY2014 annual result was $1.8 million, down 50.07% from the prior year.
Receivables eased to $1.0 million in Q1 2022 per SLS's latest filing, from $1.8 million in the prior quarter.
Over five years, Receivables peaked at $1.0 million in Q1 2022 and troughed at $1.0 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	SELLAS Life Sciences	1.39 Bn	1.39 Bn	-	-

Download Data